prosigna.com
Prosigna® | Home
http://prosigna.com/x-us
Prosigna is 510(k) cleared and CE marked. Prosigna is available to healthcare professionals in the United States, in markets that recognize the CE mark, and/or in which Prosigna is registered. Recognized as one of. Top 10 Innovations of 2013. Now included 4 Clinical Practice Guidelines. This site is intended for non-US residents only. Prosigna has been added to the ESMO Clinical Practice Guidelines Annals of Oncology 26 (Supplement 5): v8 v30, 2015. Identifying clinically relevant prognostic subgroups of...
prosignatest.fr
Prosigna® | Sitemap
http://prosignatest.fr/sitemap
Ce site est exclusivement destiné aux personnes résidant en dehors des États-Unis. Study confirms ability of the Prosigna assay to assess risk of late distant recurrence. ABCSG-8 Clinical Validation Study (. TransATAC Clinical Validation Study (. Prognostic factors in late recurrence (. Top Ten Innovations of 2013. Analytical validation study shows precision and reproducibility of PAM50-based Prosigna (. NanoString launches Prosigna Patient Support to help patients gain access to Prosigna.
prosigna.es
Prosigna® | Resumen de datos
http://www.prosigna.es/data-summary-analytical-validation
Centros que realizan el test Prosigna. Solicitar un test Prosigna. Esta página va destinada únicamente a no residentes en EE. UU. Centros que realizan el test Prosigna. Solicitar un test Prosigna. Download the updated Prosigna Package Insert and nCounter Dx User Manual:. Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From ABCSG-8 (. NanoString launches Prosigna Patient Support to help patients gain access to Prosigna. Top Ten Innovations of 2013.
prosignatest.fr
Prosigna® | Combined analysis
http://prosignatest.fr/data-summary-analytical-validation/combined-analysis
Ce site est exclusivement destiné aux personnes résidant en dehors des États-Unis. Study confirms ability of the Prosigna assay to assess risk of late distant recurrence. ABCSG-8 Clinical Validation Study (. TransATAC Clinical Validation Study (. Prognostic factors in late recurrence (. Top Ten Innovations of 2013. Analytical validation study shows precision and reproducibility of PAM50-based Prosigna (. NanoString launches Prosigna Patient Support to help patients gain access to Prosigna. Les deux étude...
prosigna.com
Prosigna® | Downloads
http://prosigna.com/x-us/downloads
Prosigna is 510(k) cleared and CE marked. Prosigna is available to healthcare professionals in the United States, in markets that recognize the CE mark, and/or in which Prosigna is registered. Recognized as one of. Top 10 Innovations of 2013. Now included 4 Clinical Practice Guidelines. This site is intended for non-US residents only. May 26, 2016. Cigna Issues Positive Coverage Decision for NanoString’s Prosigna Breast Cancer Assay. May 9, 2016.
prosignatest.fr
Prosigna® | Ordering
http://prosignatest.fr/ordering
Ce site est exclusivement destiné aux personnes résidant en dehors des États-Unis. Study confirms ability of the Prosigna assay to assess risk of late distant recurrence. ABCSG-8 Clinical Validation Study (. TransATAC Clinical Validation Study (. Prognostic factors in late recurrence (. Top Ten Innovations of 2013. Analytical validation study shows precision and reproducibility of PAM50-based Prosigna (. NanoString launches Prosigna Patient Support to help patients gain access to Prosigna.
prosigna.es
Prosigna® | Análisis combinado
http://www.prosigna.es/data-summary-analytical-validation/combined-analysis
Centros que realizan el test Prosigna. Solicitar un test Prosigna. Esta página va destinada únicamente a no residentes en EE. UU. Centros que realizan el test Prosigna. Solicitar un test Prosigna. Download the updated Prosigna Package Insert and nCounter Dx User Manual:. Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From ABCSG-8 (. NanoString launches Prosigna Patient Support to help patients gain access to Prosigna. Top Ten Innovations of 2013.
prosignatest.fr
Prosigna® | Overview
http://prosignatest.fr/overview
Ce site est exclusivement destiné aux personnes résidant en dehors des États-Unis. Study confirms ability of the Prosigna assay to assess risk of late distant recurrence. ABCSG-8 Clinical Validation Study (. TransATAC Clinical Validation Study (. Prognostic factors in late recurrence (. Top Ten Innovations of 2013. Analytical validation study shows precision and reproducibility of PAM50-based Prosigna (. NanoString launches Prosigna Patient Support to help patients gain access to Prosigna. Selon les reco...
SOCIAL ENGAGEMENT